Latest filings (excl ownership)
DEF 14A
Definitive proxy
15 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
8-K
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder following Positive Results of PALISADE-2
1 Apr 24
EFFECT
Notice of effectiveness
1 Mar 24
S-3
Shelf registration
13 Feb 24
8-K
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update
13 Feb 24
10-Q
2024 Q3
Quarterly report
13 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
3 Jan 24
10-Q
2024 Q2
Quarterly report
9 Nov 23
8-K
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
9 Nov 23
8-K/A
Other Events
6 Nov 23
8-K
Other Events
6 Nov 23
8-K
Departure of Directors or Certain Officers
26 Oct 23
8-K
Entry into a Material Definitive Agreement
4 Oct 23
424B5
Prospectus supplement for primary offering
3 Oct 23
8-K
Other Events
2 Oct 23
8-K
Submission of Matters to a Vote of Security Holders
29 Sep 23
8-K
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
12 Sep 23
8-K
Vistagen to receive $1.5 million and Fuji to obtain time-limited exclusive negotiation period for the Japanese market
8 Sep 23
8-K
Vistagen Appoints Cindy Anderson as Chief Financial Officer
22 Aug 23
10-Q
2024 Q1
Quarterly report
10 Aug 23
8-K
Results of Operations and Financial Condition
10 Aug 23
424B5
Prospectus supplement for primary offering
8 Aug 23
8-K
Vistagen Announces Positive Top-Line Results from Phase 3
7 Aug 23
DEFA14A
Additional proxy soliciting materials
28 Jul 23
DEF 14A
Definitive proxy
28 Jul 23
8-K
Other Events
18 Jul 23
8-K
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
13 Jul 23
8-K
Departure of Directors or Certain Officers
7 Jul 23
424B5
Prospectus supplement for primary offering
30 Jun 23
10-K
2023 FY
Annual report
28 Jun 23
8-K
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
28 Jun 23
8-K
Other Events
23 Jun 23
8-K
Other Events
21 Jun 23
8-K
Vistagen Announces European Patent Office Intention to Grant New
13 Jun 23
8-K
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes
7 Jun 23
8-K
Vistagen Announces Stockholder-Approved Reverse Stock Split
6 Jun 23
8-K
Other Events
1 Jun 23
8-K
Regulation FD Disclosure
27 Apr 23
Latest ownership filings
4
Mary L. Rotunno
6 Mar 24
4
JERRY B GIN
6 Mar 24
4
Margaret M FitzPatrick
6 Mar 24
4
Joanne Curley
6 Mar 24
4
Ann Michelle Cunningham
6 Mar 24
4
JON S SAXE
6 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
GREAT POINT PARTNERS LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G
VANGUARD GROUP INC
13 Feb 24
4
Reid G. Adler
3 Jan 24
4
Shawn Singh
3 Jan 24
3
Joshua S. Prince
3 Nov 23
SC 13G
TCG Crossover GP II, LLC
16 Oct 23
SC 13G
BIOTECHNOLOGY VALUE FUND L P
16 Oct 23
SC 13G
CITADEL ADVISORS LLC
16 Oct 23
SC 13G
GREAT POINT PARTNERS LLC
12 Oct 23
4
Change in insider ownership
6 Oct 23
SC 13G/A
COMMODORE CAPITAL LP
6 Oct 23
SC 13G
Point72 Asset Management, L.P.
5 Oct 23
4
Cynthia Lynn Anderson
23 Aug 23
3
Cynthia Lynn Anderson
23 Aug 23
SC 13G
COMMODORE CAPITAL LP
9 Aug 23
4
Change in insider ownership
9 Aug 23
3
Initial statement of insider ownership
9 Aug 23
SC 13G/A
BlackRock Inc.
7 Jul 23
4
Shawn Singh
5 Jul 23
4
Reid G. Adler
5 Jul 23
4
JERROLD DUANE DOTSON
5 Jul 23
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 23
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 23
SC 13G/A
ACUTA CAPITAL PARTNERS, LLC
14 Feb 23
SC 13G/A
BlackRock Inc.
1 Feb 23
SC 13G/A
FRANKLIN RESOURCES INC
1 Feb 23
4
JERROLD DUANE DOTSON
3 Jan 23
4
Shawn Singh
3 Jan 23
4
JERRY B GIN
22 Aug 22
4
Reid G. Adler
19 Aug 22
4
Shawn Singh
18 Aug 22